Patents by Inventor Stacy Jo Keding

Stacy Jo Keding has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Ghrelin 0-acyl transferase inhibitors
    Patent number: 10227310
    Abstract: The present invention provides novel GOAT inhibitors and their salts and pharmaceutical compositions thereof.
    Type: Grant
    Filed: April 13, 2016
    Date of Patent: March 12, 2019
    Assignee: Eli Lilly and Company
    Inventors: Christopher Stanley Galka, Erik James Hembre, Nicholas Allan Honigschmidt, Maria Angeles Martinez-Grau, Gema Ruano Plaza, Almudena Rubio, Stacy Jo Keding, Daryl Lynn Smith
  • GHRELIN 0-ACYL TRANSFERASE INHIBITORS
    Publication number: 20180079729
    Abstract: The present invention provides novel GOAT inhibitors and their salts and pharmaceutical compositions thereof.
    Type: Application
    Filed: April 13, 2016
    Publication date: March 22, 2018
    Inventors: Christopher Stanley Galka, Erik James Hembre, Nicholas Allan Honigschmidt, Maria Angeles Martinez-Grau, Gema Ruano Plaza, Almudena Rubio, Stacy Jo Keding, Daryl Lynn Smith
  • 1, 5-diphenyl-3-benzylamino-1, 5-dihydropyrrolidin-2-one as CB1 receptor modulators
    Patent number: 8168659
    Abstract: Compounds and pharmaceutical compositions comprising compounds of the Formula as CB1 receptor inverse agonists useful for reducing body weight in mammals, treating cognitive impairment associated with schizophrenia, and mitigating treatment emergent weight gain observed during treatment with antipsychotics.
    Type: Grant
    Filed: October 22, 2007
    Date of Patent: May 1, 2012
    Assignee: Eli Lilly and Company
    Inventors: David Scott Coffey, Jingdan Hu, Stacy Jo Keding, Joseph Herman Krushinski, Jr., John Mehnert Schaus, David Edward Tupper
  • 1, 5-DIPHENYL-3-BENZYLAMINO-1, 5-DIHYDROPYRROLIDIN-2-ONE AS CB1 RECEPTOR MODULATORS
    Publication number: 20090275618
    Abstract: Compounds and pharmaceutical compositions of Formula (I) by blockade of the CB1 receptors via an inverse agonism mechanism which are useful for reducing body weight in mammals, cognitive impairment associated with schizophrenia, mitigating treatment emergent weight gain observed during treatment with antipsychotics and have increased bioavailability.
    Type: Application
    Filed: October 22, 2007
    Publication date: November 5, 2009
    Inventors: David Scott Coffey, Jingdan Hu, Stacy Jo Keding, Joseph Herman Krushinski, JR., John Mehnert Schaus, David Edward Tupper